Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Landau

Showing results (101-110 of 104) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 104 results.
Oncogene|June 2, 2025
An FGFR-p53 developmental signaling axis drives salivary cancer progressionAdele M Musicant, Julia M R Billington, Jeffrey S Damrauer, et al.
Oncogene|June 20, 2025
Correction: An FGFR-p53 developmental signaling axis drives salivary cancer progressionAdele M Musicant, Julia M R Billington, Jeffrey S Damrauer, et al.
International Journal of Radiation Oncology, Biology, Physics|December 7, 2019
Long-Term Results from the IDEAL-CRT Phase 1/2 Trial of Isotoxically Dose-Escalated Radiation Therapy and Concurrent Chemotherapy for Stage II/III Non-small Cell Lung CancerJohn D Fenwick, David B Landau, Angela T Baker, et al.
International Journal of Radiation Oncology, Biology, Physics|June 15, 2016
IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung CancerDavid B Landau, Laura Hughes, Angela Baker, et al.
Pageof 11

Showing results (101-110 of 104) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 104 results.
Oncogene|June 2, 2025
An FGFR-p53 developmental signaling axis drives salivary cancer progressionAdele M Musicant, Julia M R Billington, Jeffrey S Damrauer, et al.
Oncogene|June 20, 2025
Correction: An FGFR-p53 developmental signaling axis drives salivary cancer progressionAdele M Musicant, Julia M R Billington, Jeffrey S Damrauer, et al.
International Journal of Radiation Oncology, Biology, Physics|December 7, 2019
Long-Term Results from the IDEAL-CRT Phase 1/2 Trial of Isotoxically Dose-Escalated Radiation Therapy and Concurrent Chemotherapy for Stage II/III Non-small Cell Lung CancerJohn D Fenwick, David B Landau, Angela T Baker, et al.
International Journal of Radiation Oncology, Biology, Physics|June 15, 2016
IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung CancerDavid B Landau, Laura Hughes, Angela Baker, et al.
Pageof 11